Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naive Patients With Malignant Pleural Mesothelioma

Trial Profile

Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naive Patients With Malignant Pleural Mesothelioma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs CBP 501 (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
  • Indications Mesothelioma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CanBas
  • Most Recent Events

    • 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 01 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top